Írland - enska - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - paliperidone - prolonged-release tablet - 3 milligram(s) - paliperidone

Írland - enska - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - paliperidone - prolonged-release tablet - 6 milligram(s) - paliperidone

Írland - enska - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - paliperidone - prolonged-release tablet - 9 milligram(s) - paliperidone

Evrópusambandið - enska - EMA (European Medicines Agency)

janssen-cilag international nv - paliperidone palmitate - schizophrenia - psycholeptics - trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.

Bandaríkin - enska - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - paliperidone palmitate (unii: r8p8usm8fr) (paliperidone - unii:838f01t721) - paliperidone palmitate 39 mg in 0.25 ml - invega sustenna® (paliperidone palmitate) is indicated for the treatment of: - schizophrenia in adults [see clinical studies (14.1)]. - schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants [see clinical studies (14.2)]. invega sustenna® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega sustenna® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including invega sustenna® , during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for

Ísrael - enska - Ministry of Health

j-c health care ltd - paliperidone as palmitate - extended release suspension for injection - paliperidone as palmitate 200 mg / 1 ml - paliperidone - trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product

Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)]. the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have bee

Bandaríkin - enska - NLM (National Library of Medicine)

inventia healthcare limited - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)]. the efficacy of paliperidone in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)]. the efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults. paliperidoneis contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone is a metabolite of risperidone. pregnancy exposure reg

Írland - enska - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - paliperidone - prolonged-release tablet - 3 milligram(s) - other antipsychotics; paliperidone

Írland - enska - HPRA (Health Products Regulatory Authority)

krka d.d., novo mesto - paliperidone - prolonged-release tablet - 6 milligram(s) - other antipsychotics; paliperidone